Cerebrovascular CO2 Reactivity during Anesthesia in Patients with Diabetes Mellitus and Peripheral Vascular Disease
Kawata, Ryuichi MD; Nakakimura, Kazuhiko MD; Matsumoto, Mishiya MD; Kawai, Kouji MD; Kunihiro, Mitsuru MD; Sakabe, Takefumi MD
Background: Diabetes mellitus (DM) and systemic atherosclerosis are risk factors for stroke. Although the origins of increased risk are complex, one possibility is that cerebrovascular reactivity is impaired and does not allow the brain to compensate for aberrations in physiology. The current study tested this issue by evaluating mean blood flow velocity of the middle cerebral artery (Vmca) and carbon dioxide reactivity during anesthesia in patients with DM and peripheral vascular disease (PVD).
: Fifty‐two patients were observed: 20 patients with DM (the DM group), 12 patients with PVD (the PVD group), and 20 patients classified as American Society of Anesthesiologists physical status 1 or 2 (the control group). The Vmca was measured using transcranial Doppler ultrasonography during isoflurane‐nitrous oxide anesthesia. After measuring baseline Vmca at a partial pressure of carbon dioxide in arterial blood (PaCO2
) of 37.7 +/− 4.5 mmHg (mean +/− SD), measurements were repeated at a PaCO
) of 44.2 +/− 3.8 mmHg, and the carbon dioxide reactivity (absolute value: cm [middle dot] s‐1
[middle dot] mmHg‐1
; relative value: percentage of baseline Vmca/mmHg) was calculated.
: The baseline Vmca of the DM group (51 +/− 12 cm/s) was significantly greater than those of the control group (42 +/− 6 cm/s) and the PVD group (42 +/− 13 cm/s). The absolute and relative values of carbon dioxide reactivity in the DM group (3.1 +/− 1.3 cm [middle dot] s‐1
[middle dot] mmHg‐1
; 6.3 +/− 2.4%/mmHg) were significantly greater than or equivalent to those of the control group (2.3 +/− 0.8 cm [middle dot] s (‐1
) [middle dot] mmHg‐1
; 5.3 +/− 1.7%/mmHg), respectively. In the PVD group, the baseline Vmca was equivalent to the control group, but the carbon dioxide reactivity (1.1 +/− 0.5 cm [middle dot] s‐1
[middle dot] mmHg (‐1
); 2.8 +/− 1.2%/mmHg) was significantly less.
Conclusions: The patients with DM have increased baseline cerebral blood flow velocity and normal carbon dioxide reactivity during anesthesia. The patients with PVD have decreased carbon dioxide reactivity, but baseline flow velocity is maintained.
DIABETES mellitus (DM) and atherosclerosis are risk factors for ischemic cerebrovascular disease. [1‐3]
Although the origins of increased risk are complex, one possibility is that cerebrovascular reactivity is impaired and does not allow the brain to compensate for aberrations in physiology. Results of some previous studies were inconsistent regarding basal cerebral blood flow (CBF) and cerebrovascular reactivity in awake diabetic humans. [4‐8]
To the best of our knowledge, no study has evaluated cerebral circulatory state and cerebrovascular reactivity during anesthesia in patients with DM or peripheral vascular disease (PVD) in the lower extremities. The current study, therefore, was designed to evaluate cerebral circulatory state, including carbon dioxide reactivity, during general anesthesia in patients with DM and PVD using noninvasive transcranial Doppler ultrasonography.
Materials and Methods
Patients and Preoperative Assessment
Fifty‐two patients scheduled for nonneurosurgical elective surgery during general anesthesia were enrolled in the study: 20 patients with DM (the DM group), 12 patients with PVD (the PVD group) of the lower extremities, and 20 patients who were age matched and classified as American Society of Anesthesiologists physical status 1 or 2 (the control group). The patients with apparent histories of ischemic cerebrovascular disease were excluded from the study. The study protocol was approved by the Ethical Committee for Human Study of the Yamaguchi University Hospital, and informed consent was obtained from each patient.
The day before surgery, blood pressure and heart rate were measured and recorded while the patients were resting. Patient medical histories, including ischemic heart disease and diabetic complications, were obtained from interviews and the clinical recordings.
Anesthesia and Monitoring
All patients fasted from midnight on the night before surgery. All oral hypoglycemic agents and insulin were withheld on the morning of surgery in patients in the DM group. The patients were premedicated with 0.25 to 0.5 mg atropine sulfate and 25 to 50 mg hydroxyzine or 2 or 3 mg midazolam administered intramuscularly. Anesthesia was induced with 4 mg/kg thiopental and 0.15 mg/kg vecuronium, tracheas were intubated, and the lungs were mechanically ventilated. Anesthesia was maintained with 1% isoflurane (end‐tidal) in 50% nitrous oxide and oxygen. In addition, fentanyl was administered intermittently (total dose, 100 ‐ 200 [micro sign]g). Acetate and Ringer's solution was infused intravenously (5 ‐ 8 ml [middle dot] kg‐1 [middle dot] h‐1), and the blood glucose concentration was measured by enzymatic analysis (Accutrend, Boehringer‐Mannheim, Mannheim, Germany). The procedures were orthopedic surgery or laparotomy in the control and DM groups and aortofemoral bypass, femoropopliteal bypass, or both, in the PVD group. Before induction of anesthesia, an epidural catheter was inserted in patients scheduled for laparotomy, but no drug was administered via the epidural catheter until all study measurements were obtained. A radial artery was cannulated for direct monitoring of arterial blood pressure, for arterial blood sampling for blood gas analysis, and to determine hemoglobin, blood glucose, and electrolyte concentrations. The nasopharyngeal temperature (Temp) was monitored and maintained using a warming blanket (Medi‐Therm II, Gaymar, New York, NY). Pulse oximetry was monitored, and end‐tidal carbon dioxide tension and concentrations of isoflurane and nitrous oxide were assessed continuously with an infrared analyzer (CAPNOX; Nippon Colin, Komaki, Japan).
Determination of Vmca and Cerebrovascular Carbon Dioxide Reactivity during Anesthesia
After induction of anesthesia, a 2‐MHz pulsed transcranial Doppler probe was attached to the patient's head at the left “temporal window,” and the mean blood flow velocity of the middle cerebral artery (Vmca) was measured continuously (TC 2‐64; EME, Uberlingen, Germany). After the appropriate signals were identified at a depth of 45 ‐ 55 mm, the probe was fixed using a probe holder (model IMP‐F/536B; EME), so as not to change the insonating angle. Because the velocity fluctuated with the respiration cycle, the value during end‐expiration was recorded.
More than 1 h ([almost equal to] 1.5 h after anesthesia induction) after making the incision, we measured baseline Vmca (at an end‐tidal carbon dioxide tension of approximately 35 mmHg), while anesthesia was maintained with isoflurane, 1% (end‐tidal) in 50% nitrous oxide and oxygen. After obtaining baseline Vmca and blood samples for analysis of blood gases, blood glucose, hemoglobin, and electrolyte concentrations, we increased the end‐tidal carbon dioxide tension by adding a dead‐space tube of approximately 100‐ml volume to the endotracheal tube and reducing the ventilatory frequency by 1 or 2 breaths/min. This resulted in an increase in the partial pressure of carbon dioxide in arterial blood (PaCO2) of approximately 7 or 8 mmHg within a few minutes. Measurements were repeated when the end‐tidal carbon dioxide tension was increased and remained stable for 5 ‐ 10 min. Small doses of vecuronium (2 mg) were administered intravenously to prevent spontaneous respiration during hypercapnia.
The carbon dioxide reactivity in each patient was calculated as both the absolute change in Vmca (cm [middle dot] s‐1
[middle dot] mmHg (‐1
)) and the percentage change in Vmca (percentage of the baseline Vmca/mmHg) per each millimeter of mercury change in PaCO2
using the following formula: The absolute carbon dioxide reactivity Equation 1
The relative carbon dioxide reactivity Equation 2
where Delta Vmca is the difference between the flow velocity after PaCO2
elevation and the baseline flow velocity, and Delta PaCO2
is the difference between the final PaCO2
and the baseline PaCO2
All data are reported as mean +/− SD. An analysis of variance was used for intergroup comparisons of preoperative physiologic data and calculated carbon dioxide reactivity. The chi‐squared test was used to compare the gender distribution. Repeated‐measures analysis of variance was used for intergroup comparisons of physiologic data (including Vmca) during the carbon dioxide reactivity study. Fisher's protected least significant difference was used for post hoc test. P < 0.05 was considered significant.
) shows patient characteristics. There were no significant differences among the three groups in age, gender distribution, height, weight, or resting mean arterial pressure and heart rate.
and Table 3
) show clinical data and Vmca in the DM and the PVD groups, respectively. One patient (patient 6) had diabetic retinopathy and nephropathy and was taking no medication at admission, but no other patients had such diabetic complications. Nine of 12 PVD patients were hypertensive, and 8 patients were prescribed antihypertensive drugs.
) shows the values for Vmca, PaCO2
), mean arterial pressure, heart rate, temperature, hemoglobin, and blood glucose. There were no significant changes in mean arterial pressure, heart rate, temperature, and hemoglobin, blood glucose, and electrolyte concentrations (data not shown) during the study. The baseline Vmca in the DM group was significantly greater than that of the control and the PVD group, but there was no significant difference between the PVD and the control group. The Vmca (post) values in all groups were significantly increased with PaCO2
) shows the cerebrovascular carbon dioxide reactivity. The absolute value of carbon dioxide reactivity in the DM group (3.1 +/− 1.3 cm [middle dot] s‐1
[middle dot] mmHg‐1
) was significantly greater than in the control group (2.3 +/− 0.8 cm [middle dot] s‐1
[middle dot] mmHg‐1
), although the relative value (6.3 +/− 2.4%/mmHg‐1
) was not different from control (5.3 +/− 1.7%/mmHg‐1
). The absolute value (1.1 +/− 0.5 cm [middle dot] s‐1
[middle dot] mmHg‐1
) and the relative value (2.8 +/− 1.2%/mmHg‐1
) of carbon dioxide reactivity in the PVD group were significantly less than in the control group and the DM group. In two diabetic patients with PVD (patients 2 and 11), the Vmca and carbon dioxide reactivity were similar to those of other patients with PVD.
The principal findings of the current study are (1) that the baseline Vmca in the DM group was significantly greater than in the control group; (2) that the absolute and relative values of carbon dioxide reactivity in the DM group were significantly greater than or equivalent to the control group, respectively; and (3) that the baseline Vmca in the PVD group was equivalent to the control group, but the carbon dioxide reactivity was significantly less than in the control group.
In interpreting our results, it seems justified to first consider the validity of the transcranial Doppler ultrasonography and the possibility of the influence of surgical stimulation. The flow velocity determined by transcranial Doppler ultrasonography is not equivalent to CBF. However, an excellent correlation between relative changes in flow velocity and changes in CBF has been reported. 
In the current study, the baseline Vmca in the control group was 42 +/− 6 cm/s (PaCO2
37 +/− 3 mmHg) during isoflurane, 1%, and 50% nitrous oxide anesthesia supplemented with fentanyl. Because we did not measure flow velocity while the patients were awake, we do not know whether flow velocity was increased or decreased by this anesthetic regimen. The observed carbon dioxide reactivity of 2.3 +/− 0.8 cm [middle dot] s‐1
[middle dot] mmHg‐1
(5.3 +/− 1.7%/mmHg) in the control group is comparable to that reported by others. 
The current study was performed during surgery using a stable general anesthetic. Surgical procedures are not identical, but we chose study periods when the surgical stimulation intensity was considered to be minimal. The mean arterial pressure and the heart rate during the study periods were nearly equal to the preoperative resting values, with minimum fluctuation, and did not differ among the three groups. Therefore, we think that the influence of the difference in the magnitude of surgical stimulation is minimal.
Cerebral Blood Flow Velocity and Cerebrovascular Carbon Dioxide Reactivity in Diabetic Patients
In diabetic patients, the baseline Vmca was significantly greater than in the control group (51 +/− 12 vs. 42 +/− 6 cm/s). The higher CBF has been reported in patients with short‐duration insulin‐dependent diabetes mellitus who have no diabetic complications 
and in patients with long‐duration but well‐controlled insulin‐dependent diabetes. 
However, Wakisaka et al. 
reported reduced regional CBF in elderly patients with long‐standing non‐insulin‐dependent diabetes. Thirty percent of these patients had retinopathy, neuropathy, nephropathy, or all of these complications. Rodriguez et al. 
observed an inverse correlation between basal global CBF and the duration of DM. It is not clear why these contradictory results (decreased, unchanged, or even increased CBF) have been observed. We assume that differences in the level and duration of hyperglycemia and in the severity of vascular disease may be responsible for the difference in reported results.
Sieber et al. 
reported in dogs that chronic hyperglycemia associated with pancreatectomy increased CBF and the cerebral metabolic rate for oxygen. However, their subsequent study did not show any differences in CBF or the cerebral metabolic rate for oxygen between the control (nonhyperglycemic) and chronic diabetic (hyperglycemic) dogs when they were either awake or anesthetized with pentobarbital and fentanyl. 
The authors speculated that the different results were caused by the elimination of the acute surgical stress in the latter study. Because we did not measure flow velocity in awake patients or in those without surgical stress, we cannot rule out the possibility of differential sensitivity to surgical stress or anesthetics in diabetic patients.
For cerebrovascular carbon dioxide reactivity, Dandona et al. 
reported that CBF decreased in response to the inhalation of 5% carbon dioxide in 45% of diabetic patients (CBF was increased in 38% of patients and unchanged in 17%). They concluded that diabetic persons are at increased risk of cerebrovascular disease because they cannot compensate with an increased CBF when necessary. These abnormalities were attributed to microangiopathy in the cerebral vessels. Griffith et al. 
also reported some DM patients with decreased carbon dioxide reactivity. In rats, Pelligrino and Albrecht 
reported unchanged carbon dioxide reactivity in the early and late stages (prolonged duration) of a streptozotocin‐induced hyperglycemia model, despite the apparent blunted response or loss of vasodilative response to insulin‐induced hypoglycemia. This suggested that there was selective suppression of the cerebral vasodilatory capacity in the chronically hyperglycemic diabetic patients. The authors speculated that the difference between their study and previous studies could be a result of the species or the differences in the severity and stability of hyperglycemia during an extended period. The latter may lead to a variability in vascular disease and reactivity.
It has long been believed that cerebrovascular carbon dioxide reactivity is influenced by basal cerebrovascular resistance (conductance), 
and thus the higher the baseline flow, the steeper the carbon dioxide reactivity. In the current study, when evaluated with the absolute carbon dioxide reactivity, carbon dioxide reactivity in the DM group was significantly greater than in the control group (3.1 +/− 1.3 vs. 2.3 +/− 0.8 cm [middle dot] s‐1
[middle dot] mmHg‐1
), and this agrees with that assumption. However, when evaluated with the relative carbon dioxide reactivity, no statistical significance was seen between the DM and the control group (6.3 +/− 2.4 vs. 5.3 +/− 1.7% mmHg). Because the transcranial Doppler ultrasonography method does not provide absolute changes but gives relative changes in CBF, carbon dioxide reactivity might be best assessed by the relative changes. Considering this methodologic characteristic, our results indicate that the DM patients examined in the current study have a maintained carbon dioxide reactivity (not increased). However, it deserves discussion concerning the heterogeneity in the DM group. Although the available data were limited in the current study (only in 12 patients), the recent glycosylated hemoglobin (hemoglobin A1c) value and carbon dioxide reactivity were correlated inversely, suggesting that the poor glycemic control exhibits the possibility of reduced reactivity of cerebral vessels. The most diabetic patients in this study were free from clinical symptoms of microangiopathy (retinopathy, nephropathy) and macroangiopathy (coronary artery disease, carotid artery disease, and so forth). Although not completely ruled out, atherosclerosis in our DM patients may not be a major factor affecting the results. Our results may indicate that the diabetic patients with poor glycemic control may be at increased risk of ischemia because of impaired cerebrovascular reactivity, although this ought to be further determined in a much larger population of diabetic patients.
Cerebral Blood Flow Velocity and Cerebrovascular Carbon Dioxide Reactivity in Peripheral Vascular Disease
The patients with PVD are considered to have generalized atherosclerosis that increases a risk of cerebral infarction, myocardial infarction, renal dysfunction, and so forth. Although we could not afford to perform angiography to assess the cerebral arteries and carotid arteries before operation, atherosclerotic changes in these arteries most likely were present. A decreased CBF might be anticipated in the patients with atherosclerosis in the cerebral arteries and carotid arteries, but in the current study the baseline Vmca during general anesthesia was not different from that of control patients (42 +/− 13 vs. 42 +/− 6 cm/s). Sugimori et al. 
showed no differences in the average Vmca among patients with or without carotid artery occlusive disease and minor stroke. Heistad et al. 
also showed that baseline CBF was similar in monkeys with or without atherosclerosis of the carotid arteries.
Regarding the carbon dioxide reactivity, absolute and relative values of carbon dioxide reactivity both were decreased compared with the control group (2.3 +/− 0.8 vs. 1.1 +/− 0.5 cm [middle dot] s‐1
[middle dot] mmHg‐1
; 5.3 +/− 1.7 vs. 2.8 +/− 1.2%/mmHg). Some previous studies reported impaired cerebrovascular carbon dioxide reactivity in patients with ischemic cerebrovascular disease 
and in those with carotid artery disease. 
Thiel et al. 
studied preoperative cerebrovascular carbon dioxide reactivity using transcranial Doppler ultrasonography in carotid artery disease. In their 94 patients undergoing carotid endarterectomy, carbon dioxide reactivity was impaired in 12 (<or= to 1.5%/mmHg, no actual values were presented). The speculated that the impaired carbon dioxide reactivity may be a result of the vasodilatation of cerebral arterioles to maintain cerebral perfusion in vascular occlusive disease. Although our patients had no apparent history or symptoms of ischemic cerebrovascular disease, carbon dioxide reactivity was decreased during general anesthesia. The mechanism for decreased carbon dioxide reactivity is not clear. Nine of 12 patients in the PVD group were hypertensive and were medicated with antihypertensive drugs. Tominaga et al. 
reported no carbon dioxide reactivity difference between hypertensive and normotensive patients, and the calcium channel blocker nicardipine has been reported to have no significant influence on carbon dioxide reactivity. [20,21]
Therefore, we think hypertension itself and preoperative antihypertensive drugs did not have a significant influence on the results of carbon dioxide reactivity. Whatever the mechanism for decreased carbon dioxide reactivity, our results indicate that when patients with PVD are anesthetized, even if they have no apparent history of ischemic cerebrovascular disease, they are at risk for cerebral hemodynamic impairment because they may exhibit poor reserve to increase CBF when necessary.
In conclusion, the baseline Vmca was increased and the carbon dioxide reactivity was maintained in the diabetic patients during anesthesia. In the patients with PVD, the baseline Vmca was maintained, but the carbon dioxide reactivity was decreased.
1. Bell DSH: Stroke in the diabetic patient. Diabetes Care 1994; 17:213-9
2. Dennis MS, Bamford JM, Sandercock PAG, Warlow CP: A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes: The Oxfordshire Stroke Project. Stroke 1989; 20:1494-9
3. Tonelli C, Finzi G, Catamo A, Silvestrini C, Squeri M, Mombelloni A, Ponari O: Prevalence and prognostic value of peripheral arterial disease in stroke patients. Int Angiol 1993; 12:342-3
4. Griffith DNW, Saimbi S, Lewis C, Tolfree S, Betteridge DJ: Abnormal cerebrovascular carbon dioxide reactivity in people with diabetes. Diabetic Med 1987; 4:217-20.
5. Grill V, Gutniak M, Bjorkman O, Lindqvist M, Stone-Elander S, Seitz RJ, Blomqvist G, Reichard P, Widen L: Cerebral blood flow and substrate utilization in insulin-treated diabetic subjects. Am J Physiol 1990; 258:E813-20
6. Wakisaka M, Nagamachi S, Inoue K, Morotomi Y, Nunoi K, Fujishima M: Reduced regional cerebral blood flow in aged noninsulin-dependent diabetic patients with no history of cerebrovascular disease: Evaluation by N-isopropyl-123 I-p-iodoamphetamine with single-photon emission computed tomography. J Diabetic Complications 1990; 4:170-4
7. Rodriguez G, Nobili F, Celestino MA, Francione S, Gulli G, Hassan K, Marenco S, Rosadini G, Cordera R: Regional cerebral blood flow and cerebrovascular reactivity in IDDM. Diabetes Care 1993; 16:462-8
8. Dandona P, James IM, Newbury PA, Woollard ML, Beckett AG: Cerebral blood flow in diabetes mellitus: Evidence of abnormal cerebrovascular reactivity. BMJ 1978; 2:325-6
9. Bishop CCR, Powell S, Rutt D, Browse NL: Transcranial Doppler measurement of middle cerebral artery blood flow velocity: A validation study. Stroke 1986; 17:913-5
10. Matta BF, Lam AM, Mayberg TS, Eng CC, Strebel S: Cerebrovascular response to carbon dioxide during sodium nitroprusside- and isoflurane-induced hypotension. Br J Anaesth 1995; 74:296-300
11. Sieber FE, Brown PR, Wu Y, Koehler RC, Traystman RJ: Cerebral blood flow responsivity to CO2 in anesthetized chronically diabetic dogs. Am J Physiol 1993; 264:H1069-75
12. Sieber FE, Brown PR, Wu Y, Koehler RC, Traystman RJ: Cerebral blood flow and metabolism in dogs with chronic diabetes. Anesthesiology 1993; 79:1013-21
13. Pelligrino DA, Albrecht RF: Chronic hyperglycemic diabetes in the rat is associated with a selective impairment of cerebral vasodilatory responses. J Cereb Blood Flow Metab 1991; 11:667-77
14. Ackerman RH, Zilkha E, Bull JWD, Du Boulay GH, Marshall J, Russell RWR, Symon L: The relationship of the CO2 reactivity of cerebral vessels to blood pressure and mean resting blood flow. Neurology 1973; 23:21-6
15. Sugimori H, Ibayashi S, Fujii K, Sadoshima S, Kuwabara Y, Fujishima M: Can transcranial Doppler really detect reduced cerebral perfusion states? Stroke 1995; 26:2053-60
16. Heistad DD, Marcus ML, Piegors DJ, Armstrong ML: Regulation of cerebral blood flow in atherosclerotic monkeys. Am J Physiol 1980; 239:H539-44.
17. Maeda H, Matsumoto M, Handa N, Hougaku H, Ogawa S, Itoh T, Tsukamoto Y, Kamada T: Reactivity of cerebral blood flow to carbon dioxide in various types of ischemic cerebrovascular disease: Evaluation by the transcranial Doppler method. Stroke 1993; 24:670-5
18. Thiel A, Zickmann B, Stertmann WA, Wyderka T, Hempelmann G: Cerebrovascular carbon dioxide reactivity in carotid artery disease. Anesthesiology 1995; 82:655-61
19. Tominaga S, Strandgaard S, Uemura K, Ito K, Kutsuzawa T, Lassen NA, Nakamura T: Cerebrovascular CO2 reactivity in normotensive and hypertensive man. Stroke 1976; 7:507-10
20. Kawaguchi M, Furuya H, Kurehara K, Yamada M: Effects of nicardipine on cerebral vascular responses to hypocapnia and blood flow velocity in the middle cerebral artery. Stroke 1991; 22:1170-2
21. Abe K, Iwanaga H, Shimada Y, Yoshiya I: The effect of nicardipine on carotid blood flow velocity, local cerebral blood flow, and carbon dioxide reactivity during cerebral aneurysm surgery. Anesth Analg 1993; 76:1227-33
This article has been cited 7 time(s).
StrokeDiabetic patients have an impaired cerebral vasodilatory response to hypercapnia under propofol anesthesiaStroke
Internal carotid artery haemodynamics in women with polycystic ovaries
Clinical Science, 98(6):
Anesthesia and AnalgesiaThe effect of diabetes on the interrelationship between jugular venous oxygen saturation responsiveness to phenylephrine infusion and cerebrovascular carbon dioxide reactivityAnesthesia and Analgesia
Surgery TodayAnalysis of the factors related to a decrease in jugular venous oxygen saturation in patients with diabetes mellitus during normothermic cardiopulmonary bypassSurgery Today
British Journal of Anaesthesia
Cerebrovascular carbon dioxide reactivity in patients with insulin-dependant diabetes mellitus
British Journal of Anaesthesia, 82():
Journal of Clinical AnesthesiaCerebrovascular carbon dioxide reactivity with propofol anesthesia in patients with previous strokeJournal of Clinical Anesthesia
Journal of Thoracic and Cardiovascular SurgeryRisk factors for cognitive dysfunction after coronary artery bypass graft surgery in patients with type 2 diabetesJournal of Thoracic and Cardiovascular Surgery
Cerebral blood flow velocity; glycosylated hemoglobin [hemoglobin AIC]; stroke risk; transcranial Doppler ultrasonography.
© 1998 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Highlight selected keywords in the article text.